Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA COVID-19 vaccines in children 6 months to <6 years
NCT05436834Phase 3Completed
- Sponsor
- Moderna Inc
- Start
- Jun 2022
- Primary completion
- Oct 2025
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 7
01
Overview
A Phase 3 trial of elasomeran + imelasomeran, mRNA-1273.815 in coronavirus disease 2019 (COVID-19), sponsored by Moderna Inc. Started Jun 2022; status: completed.
02
Drugs
elasomeran + imelasomeranmRNA-1273.815
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05436834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05436834.